Novo Nordisk A/S (BCBA:NVO)
Argentina · Delayed Price · Currency is ARS | Market Cap | 257.89T -30.4% |
| Revenue (ttm) | 74.58T +5.6% |
| Net Income | 26.36T +4.8% |
| EPS | 5,930.67 +5.0% |
| Shares Out | n/a |
| PE Ratio | 9.78 |
| Forward PE | 11.60 |
| Dividend | 78.51 (0.90%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 3,037 |
| Open | 8,995.00 |
| Previous Close | 8,940.00 |
| Day's Range | 8,730.00 - 9,000.00 |
| 52-Week Range | 8,480.00 - 11,920.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira. Novo Nordisk maintains a dominant lead in the rapidly expanding metabolic...
Novo Nordisk price target lowered to $40 from $47 at BMO Capital
BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $40 from $47 and keeps a Market Perform rating on the shares as part of a broader research…
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb provides high free cash flow and a deep oncology pipeline at a modest valuation. Novo Nordisk dominates the obesity and diabetes markets with exceptional net margins and steady gr...
Novo Nordisk price target lowered to DKK 296 from DKK 310 at Citi
Citi analyst Graham Parry lowered the firm’s price target on Novo Nordisk (NVO) to DKK 296 from DKK 310 and keeps a Neutral rating on the shares. Published first on…
Citigroup Lowers Novo Nordisk's Target Price to 296 DKK Amid Long-Term Profit Concerns
Citigroup Lowers Novo Nordisk's Target Price to 296 DKK Amid Long-Term Profit Concerns
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
UBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaround story. Yee sees Novo Nordisk turning its business around, but believes it could take some time.
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
Rapid weight loss can lead to issues with bone quality, particularly in older adults.
Novo Nordisk (NVO) Sees Bullish Options Activity as Stock Gains 1.69% on October 7, 2026
Novo Nordisk (NVO) Sees Bullish Options Activity as Stock Gains 1.69% on October 7, 2026
WHO Issues First Childhood Obesity Guidelines, Impacting Novo Nordisk (NVO) Focus
WHO Issues First Childhood Obesity Guidelines, Impacting Novo Nordisk (NVO) Focus
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Novo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weight-loss drug. The company lost the lead in the emerging GLP-1 space to Eli Lilly.
Novo Nordisk (NVO): Pipeline Timing Matters as GLP-1 Competition Intensifies
Novo Nordisk A/S (NVO) faces a critical inflection point in the obesity and diabetes therapeutics market as competitive pressures from... The post Novo Nordisk (NVO): Pipeline Timing Matters as GLP-1 ...
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly and shows rapid expansion with metabolic health treatments and high revenue growth. Novo Nordisk A/S maintains a strong global footprint with deep expertise in diabetes and obesity care.
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
Novo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited. Pfizer hasn't entered the GLP-1 race yet, but the company has a diversified business and a long history of success.
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
(RTTNews) - Novo Nordisk A/S (NVO), a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) informed the company that its Biologics License Application (BLA) review of den...
FDA Postpones Review of Novo Nordisk's Hemophilia A Drug, NVO Eyes 2027 U.S. Launch
FDA Postpones Review of Novo Nordisk's Hemophilia A Drug, NVO Eyes 2027 U.S. Launch
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues
The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility, the Danish drugmaker said on Friday.
Novo provides update on the denecimig Biologics License Application (BLA) in the US
Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, ...
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors
Novo has improved its pipeline through licensing deals. The recent agreements it has signed could yield powerful, differentiated weight-loss options.
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk maintains high profitability through its specialization in chronic disease management and metabolic health. Pfizer is aggressively diversifying its portfolio through strategic acquisition...
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs...
Lightning Round: Sprouts is a winner, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Sprouts Farmers Market, Taiwan Semi, Novo Nordisk, NetApp, and Kenvue.
Trump Medicare drug pricing model may apply to only four companies after exemptions
A Trump administration rule to cut hospital drug prices for Medicare patients may apply to as few as four drugmakers after exempting companies that signed separate "most favored nation" pricing agre...
Novo Nordisk's Wegovy Reduces Liver Fat In Obesity Without Diabetes
(RTTNews) - Thursday, Novo Nordisk A/S (NVO) announced a post hoc analysis of data from a STEP UP trial, showing that Wegovy reduced liver fat in adults with obesity without diabetes.
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide al...